Abstract
Recent reports by Baccarani and Tura [2], Moloney and Rosenthal [9], and Housset et al. [6] prompted us to treat 12 acute myeloid leukemia (AML) and 4 myelodysplastic Syndrome (MDS) patients with low dose cytosine arabinoside (Ara-C). In all patients, conventional chemotherapy was contraindicated because of previous inefficacy, advanced age, or heavy comorbidity. Ara-C was given in a dose of 10 mg/m2 s. c. every 12 h for 14–28 days. All patients received one or two courses. If bone marrow revealed more than 5% blasts 1 week after the end of therapy, another course was started. Patients who obtained a complete or partial remission received maintenance chemotherapy with low dose Ara-C (10 mg/m2 s. c. every 12 h) for 8 days every 3 or 4 weeks.
Department of Oncology and Hematology, University of Hamburg, Martinistr. 52, D-2000 Hamburg 20, FRG
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrey C, Beris P, Plancherel C, de Loes S, Maurice P, Chapuis B (1983) Cytosinearabinoside ä doses reduites pour le traitement des leucemies myeloides aigues. Schweiz Med Wochenschr 113: 980
Baccarani M, Tura S (1979) Differentiation of myeloid leukaemic cells: new possibilities for therapy. Br J Haematol 43: 485
Baccarani M, Zaccaria A, Bandini G, Cavazzini G, Fanin R, Tura S (1983) Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. Leuk Res 7: 539
Castaigne S, Daniel MT, Tilly H, Herait P, Degos L (1983) Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? Blood 62: 85
Hagenbeek A, Sizoo W, Löwenberg B (1983) Treatment of acute myelocytic leukemia with low-dose cytosine-arabinoside: results of a pilot study in four patients. Leuk Res 7: 443
Housset M, Daniel MT, Degos L (1982) Small dose of ARA-C in the treatment of acute myeloid leukemia: differentiation of myeloid leukaemia cells? Br J Haematol 51: 125
Lotem J, Sachs J (1974) Different blocks in the differentiation of myeloid leukemic cells. Proc Natl Acad Sei USA 71: 3507
Manoharan A (1983) Low-dose Cytarabine therapy in hypoplastic acute leukemia. N Engl J Med 309: 1652
Moloney WC, Rosenthal DS (1981) Treatment of early acute nonlymphatic leukemia with low-dose cytosine arabinoside. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern trends in human leukemia IV. Springer, Berlin Heidelberg New York, pp 59–62
Mufti GJ, Oscier DG, Hamblin TJ, Bell AJ (1983) Low doses of cytarabine in the treatment of myelodysplastic Syndrome and acute myeloid leukemia. N Engl J Med 309: 1653
Sachs L (1978) The differentiation of myeloid leukaemia cells. New possibilities for therapy. Br J Haematol 40: 509
Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, Brousse N, Mancilla F, Renoux M, Bernard JF, Boivin P (1984) Chronic myelomonocytic leukemia according to FAB Classification: analysis of 35 cases. Blood 53: 634
Wisch JS, Griffin JD, Kufe DW (1983) Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599 62
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Weh, H.J., Zschaber, R., von Paleske, A., Hossfeld, D.K. (1985). Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome by Low Dose Cytosine Arabinoside. In: Neth, R., Gallo, R.C., Greaves, M.F., Janka, G. (eds) Modern Trends in Human Leukemia VI New Results in Clinical and Biological Research Including Pediatric Oncology. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 29. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70385-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-70385-0_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-15329-0
Online ISBN: 978-3-642-70385-0
eBook Packages: Springer Book Archive